Problem Statement
- Current Limitations in Scientific Due Diligence
- Limited access to comprehensive clinical trial data hampers informed decision-making.
- Insufficient integration of scientific literature leads to
gaps in understanding therapeutic assets. - Lack of advanced analytics tools restricts predictive
modeling of clinical outcomes.
- Need for Comprehensive Data Integration
- Fragmented data sources result in incomplete market assessments and insights.
- Advanced analytics are crucial for accurately forecasting regulatory approval probabilities.
- Integrating diverse scientific databases enhances the quality of capital raising narratives.
The Complex Funding Landscape
Increased Scrutiny
Valuation Pressure
Market volatility has introduced significant unpredictability in funding windows, leading to pressure on companies to justifytheir valuations amidst fluctuating investor sentiment.
Biotech companies face multiple potential funding pathways, including venture capital, strategic partnerships, and public offerings, complicating decision-making processes.
Funding sources are expanding beyond traditional US hubs, providing biotech companies with access to international investors and diverse capital markets.
- Value Proposition
Integrating specialized databases provides comprehensive access to clinical, regulatory, and market data, improving the depth of scientific due diligence.
With enriched data, AKT can make more informed decisions, allowing for better risk assessment and strategic planning in capital raising activities.
Utilizing advanced analytics and diverse data sources positions AKT Capital ahead of competitors, delivering superior insights to clients and investors.
Scientific Rigor
AKT Capital employs a data-driven approach to assess therapeutic assets, ensuring that every recommendation is backed by robust scientific evidence.
Financial Expertise
Our team brings sophisticated valuation models and deal structuring strategies, tailored to meet the unique financial needs of biotech and healthcare companies.
Strategic Guidance
We provide personalized funding roadmaps that align with each client's growth stage, helping them navigate the complexities of capital raising..
Network Access
Leveraging our extensive connections, we facilitate introductions to over 250 specialized life sciences investors, enhancing funding opportunities for our clients.
- Approach
Partnering with AKT Capital
We integrate over 20 specialized scientific and financialdatabases, utilizing AI-powered analytics to provide competitive positioning insights and valuation benchmarks, ensuring our clients stay ahead.
Our team optimizes data presentation for maximum impact, rigorously prepares clients for technical due diligence, and develops relationships with Key Opinion Leaders (KOLs) to validate scientific claims.
We craft tailored narratives that resonate with different investor segments, developing stage-appropriate value propositions and clearly articulating competitive differentiators for our clients.
With direct relationships with over 250 life sciences investors, we provide access to strategic corporate venture funds and connections to crossover and institutional investors, maximizing funding opportunities.
- Due Diligence
Target Identification & Due Diligence
We utilize advanced AI algorithms to scan and identify promising biotech, MedTech, and pharma assets, ensuring we
focus on the most viable opportunities.
Scientific & Clinical Assessment
Our team conducts a thorough evaluation of scientific and clinical pipelines to gauge the potential of identified assets, ensuring they align with market needs.
Regulatory Pathway Analysis
We analyze the regulatory landscape to ascertain the
probability of approval, facilitating informed decision-making on potential investments.
Market Opportunity Sizing
By sizing the market opportunities and assessing competitive positioning, we help identify assets that promise significant
returns.
Management Team Evaluation
Global Buyer Identification
Conduct thorough market research and analysis to identify potential strategic buyers worldwide, focusing on companies that align with the asset's value proposition.
Private Equity & Venture Capital Mapping
Create a comprehensive database of private equity and venture capital firms, analyzing their investment preferences and historical transaction activity.
Ideal Partner Matching
Evaluate potential licensing and acquisition partners based on compatibility with the asset, market presence, and strategic goals to ensure successful collaborations.
Regional Strategy Development
Develop tailored strategies for various regions, including the US, EU, Japan, and emerging markets, to optimize outreach and engagement efforts
Confidential Outreach Management
Implement structured outreach campaigns to engage identified buyers and partners while maintaining confidentiality and leveraging secure communication protocols.
- Advisory Services
Strategic Positioning & Market Readiness
Scientific Asset Storytelling
Craft compelling narratives around scientific assets to
effectively communicate their value proposition and potential impact to investors and partners.
Financial Statement Preparation
Create and organize a comprehensive data room that
facilitates due diligence, ensuring all necessary documentation is readily accessible for potential buyers.
Corporate Governance
Enhancement
Implement best practices in corporate governance to boost investor confidence and ensure compliance with regulatory standards.
- Regulatory Strategy
Navigating Global Regulatory Frameworks
We are prioritizing a comprehensive understanding of the FDA's rigorous requirements, ensuring timely submissions and addressing feedback effectively.
We are enhancing our engagement with EMA and PMDA through early consultations to anticipate challenges and align our strategies with regional expectations.
By investing in training and resources, we are equipping our teams to navigate complex regulatory landscapes, minimizing delays and maximizing efficiency.
M&A Target Identification & Due Diligence
• Leverage AI-powered analytics to identify high-potential biotech, MedTech, and pharma assets.
• Conduct deep due diligence, assessing clinical pipeline strength, regulatory pathways, and market viability.
Valuation & Financial Modeling
• Provide risk-adjusted valuation models to guide investment decisions.
• Structure optimal deal terms with NPV, IRR, and milestone-based financial analysis.
Regulatory & Market Access Strategy
• Navigate FDA, EMA, PMDA, and global regulatory frameworks for seamless integration.
• Assess reimbursement strategies and commercialization feasibility.
Post-Merger Integration & Value Maximization
• Develop structured integration roadmaps to optimize synergies post-acquisition.
• Ensure smooth operational and scientific alignment between entities.
Who We Support
• Private Equity & Venture Capital Firms
• Corporate M&A & Strategy Teams (Pharma, Biotech, MedTech)
• Investment Banks & Institutional Investors
Strategic Positioning & Market Readiness
• Optimize your company’s narrative, financials, and pipeline for investor interest.
• Benchmark licensing and M&A deals to maximize valuation.
Investor & Partner Targeting
• Identify global strategic buyers, pharma companies, and private equity investors.
• Match with ideal licensing or acquisition partners in Japan, US, EU, and emerging markets.
Licensing & M&A Deal Structuring
• Structure term sheets, royalty models, and milestone agreements for out-licensing.
• Assist in negotiating financial and strategic terms with investors and acquirers.
Transaction Execution & Closing Support
• Provide end-to-end transaction management, from due diligence to deal closure.
• Oversee post-deal transition planning and integration.
Who We Support
• Biotech Startups & Mid-Stage Firms
• University Spin-Offs & Research Institutions
• Growth-Stage Healthcare & Life Sciences Companies
Sell-Side Advisory
For Biotech Startups, Mid-Sized Firms & Healthcare Companies Seeking Investors or Acquirers
- Why Choose AKT Capital?
Proprietary Data & AI-Driven Insights
Access exclusive market intelligence for strategic decision-making.
Global Network of Investors & Buyers
Direct connections with top-tier PE firms, pharma leaders, and acquirers.
Regulatory & Financial Expertise
End-to-end support from valuation to deal closure.
Tailored M&A & Licensing Solutions
Custom strategies that align with your business objectives.
Case Studies: Proven Success in Healthcare & Life Sciences Investment Advisory
Buy-Side Case Studies
- Case Study 1: Japanese Pharma Giant Acquires a U.S. Biotech Firm for Rare Disease Pipeline
A leading Japanese pharmaceutical company
Expand into rare disease therapeutics through a strategic acquisition
Identifying the right U.S. biotech with a strong but undervalued clinical-stage asset
AKT Capital’s Role:
Target Identification & Due Diligence
Used AI-powered scouting to identify biotech firms with promising rare disease assets.
Valuation & Risk Assessment
Conducted financial modeling & risk-adjusted projections to validate investment potential.
Regulatory & Market Entry Strategy
Assessed FDA and PMDA regulatory pathways for smooth approval post-acquisition.
Outcome:
$450M acquisition deal finalized, enabling the Japanese pharma company to enter the U.S. rare disease market with a high-growth pipeline.
- Case Study 2: Private Equity Firm Acquires European MedTech Startup to Expand Digital Health Portfolio
A healthcare-focused private equity firm
Acquire a fast-growing MedTech startup with AI-driven diagnostics
Identifying a scalable technology with regulatory approval potential
AKT Capital’s Role:
Competitive Market Benchmarking
Analyzed comparable deals and identified undervalued AI-driven MedTech firms.
Regulatory & IP Due Diligence
Verified CE-marking, FDA approval roadmap, and IP security.
Post-Merger Integration Strategy
Developed an operational roadmap for seamless acquisition and scaling.
Outcome:
$200M acquisition completed, with the MedTech startup integrated into the PE firm’s digital health portfolio and successfully launched in new markets.
Sell-Side Case Studies
- Case Study 3: Biotech Startup Secures $100M Licensing Deal with a Global Pharma Company
Early-stage biotech firm with a novel oncology therapy
Out-license its lead asset to a global pharma partner
Finding the right strategic partner willing to invest in an early-stage asset
AKT Capital’s Role:
Investor & Partner Targeting
Connected the biotech firm with global pharma players actively seeking oncology assets.
Valuation & Deal Structuring
Benchmarked similar licensing deals and structured royalties, milestones, and upfront payments.
Negotiation Support
Assisted in negotiating a favorable term sheet ensuring long-term value retention.
Outcome:
$100M licensing agreement secured, with the biotech firm retaining royalties and milestone-based payments. The deal accelerated the clinical development of their oncology asset.
- Case Study 4: University Spin-Off Biotech Raises $50M Series B from Strategic Investors
A university-affiliated biotech company specializing in gene therapy
Secure Series B funding from strategic investors and pharma partners
Convincing investors of the long-term commercial potential of an early-stage pipeline
AKT Capital’s Role:
Strategic Positioning & Market Readiness
Refined the biotech’s investment pitch and developed a compelling commercialization roadmap.
Investor Targeting & Outreach
Engaged with strategic pharma investors and venture capital firms in Japan, U.S., and Europe.
Regulatory & Reimbursement Strategy
Provided insights into regulatory approval pathways and reimbursement strategies.
Outcome:
$50M Series B secured, enabling the biotech firm to advance its pipeline into Phase 2 clinical trials with a strong partner network.
